Picture of Lite Strategy logo

LITS — Lite Strategy News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

MEI Pharma Inc expected to post a loss of $2.41 a share - Earnings Preview

* MEI Pharma Inc  MEIP.OQ   MEIP.O  is expected to show a
fall in
quarterly revenue when it reports  results on September 6
(estimated). 
    * The San Diego California-based  company is expected to
report  a
91.8% decrease in revenue to $931 thousand from $11.41 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for MEI Pharma Inc is
for a
loss of $2.41 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MEI Pharma
Inc is
$20​, above​ its last closing price of $5.42. ​​​

This summary was machine generated September 4 at 11:01 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Lite Strategy

See all news